KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Invested Capital (2016 - 2026)

Pfizer has reported Invested Capital over the past 18 years, most recently at $91.0 billion for Q1 2026.

  • Quarterly Invested Capital fell 0.53% to $91.0 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $91.0 billion through Mar 2026, down 0.53% year-over-year, with the annual reading at $87.4 billion for FY2025, 2.15% down from the prior year.
  • Invested Capital was $91.0 billion for Q1 2026 at Pfizer, up from $87.4 billion in the prior quarter.
  • Over five years, Invested Capital peaked at $102.0 billion in Q2 2023 and troughed at $83.5 billion in Q2 2022.
  • The 5-year median for Invested Capital is $91.4 billion (2025), against an average of $92.4 billion.
  • Year-over-year, Invested Capital soared 153.13% in 2022 and then fell 11.32% in 2024.
  • A 5-year view of Invested Capital shows it stood at $96.7 billion in 2022, then fell by 6.82% to $90.1 billion in 2023, then decreased by 0.93% to $89.3 billion in 2024, then decreased by 2.15% to $87.4 billion in 2025, then grew by 4.13% to $91.0 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Invested Capital are $91.0 billion (Q1 2026), $87.4 billion (Q4 2025), and $94.0 billion (Q3 2025).